The Pharma Data

NOVEMBER 19, 2020

The Company is also aiming to leverage the highly conserved structure of the SARS-CoV-2 M pro protease as a basis for the design of novel oral small molecules against predicted future variants of SARS-CoV-2 and other related human viruses. Zhang, et al, Science (2020) DOI: 10.1126/science.abb3405. References. Hilgenfeld, Febs J.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

Fierce BioTech

AUGUST 25, 2023

Your Comprehensive Guide to Analytical Testing, From Clinical to Commercial pesurya Fri, 08/25/2023 - 10:45 Tue, 10/03/2023 - 11:00 Resource Type Webinar Katie Schlipp Elliott Franco, Ph.D. Duration 60 Minutes The life science industry has been growing rapidly, primarily driven by the rise of aging population and innovation in new modalities.

Small Molecule 52

Small Molecule Clinical Development Science Treatment 52

Drug Target Review

JULY 18, 2023

AI is being used to find the targets themselves, design the drugs to manipulate that biology, and thirdly, AI is being used to support validation of those targets and drugs as part of pre-clinical development. Pharmaceutical companies are an absolutely pivotal part of the life sciences industry and ecosystem.

Drug Development 98

Drug Development Drugs Clinical Development Pharmaceutical Companies 98

Precision for Medicine

JUNE 26, 2023

Baseline Control’s expertise will become part of Project Farma, Precision for Medicine’s existing biomanufacturing strategy and execution group, expanding the scope of its manufacturing solutions for life science companies and driving greater speed and efficiency in bringing new drugs to market.

Science 40

Science Small Molecule Clinical Research Engineering 40

The Pharma Data

JUNE 28, 2021

Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer. Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine. Noria) and PSMA Therapeutics Inc.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

Nvidia Developer: Drug Discovery

MARCH 21, 2023

New supercomputing-scale large language models (LLMs) that understand biology and chemistry text are helping scientists understand proteins, small molecules, DNA, and biomedical text. These state-of-the-art AI models help generate de novo proteins and molecules and predict the 3D structures of proteins.

Small Molecule 52

Small Molecule Drugs Clinical Trials DNA 52

The Pharma Data

MAY 15, 2023

Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera Gilead Sciences, Inc. The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. Qing Dong, Ph.D., and Gene Hung, M.D.,

Small Molecule 40

Small Molecule DNA Immune Response Science 40

The Pharma Data

MAY 31, 2022

We look forward to continuing our collaboration with Biogen and the Parkinson’s community in our unified goal to develop BIIB122 as a potential treatment option for people and families living with Parkinson’s disease.”. BIIB122 is an investigational small molecule inhibitor of LRRK2 that was discovered and developed by Denali.

Disease 52

Disease Small Molecule Engineering Biosimilars 52

The Pharma Data

DECEMBER 17, 2020

Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Prior to joining Cidara, Kurtz served as head of commercial API manufacturing at Gilead Sciences.

Small Molecule 52

Small Molecule Clinical Development Engineering Pharmaceuticals 52

The Pharma Data

FEBRUARY 21, 2022

Bayer’s research and development pipeline continues to grow as the company is building on its existing competencies, such as the expertise around small molecules, while expanding into new modalities, including cell and gene therapies.

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

LifeSciVC

MARCH 1, 2023

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC The phrase ‘build it and they will come’ dates all the way back to the Old Testament, and in more recent times has been romanticized in movies like Field of Dreams , but the concept also holds true in many areas of science.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

The Pharma Data

APRIL 6, 2021

For the first time, Bayer will be presenting preclinical data on novel small molecule epidermal growth factor receptor (EGFR) exon 20 inhibitor BAY 2476568, which was discovered through the company’s strategic research alliance with the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, U.S.A. About Oncology at Bayer.

Research 52

Research Small Molecule Treatment Clinical Trials 52

The Pharma Data

JANUARY 7, 2021

Dr. Anne Prener has more than 25 years of leadership experience within life sciences companies, and currently serves as Chief Executive Officer of Imbria Inc. Dr. Prener serves on the Boards of Directors of several life science companies, Rubius Therapeutics, Kaleido Bioscience and Renovacor. Dr. Prener holds a Ph.D.

Small Molecule 40

Small Molecule Clinical Development Production Science 40

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues. Asia, and Europe.

Drug Development 52

Drug Development Treatment Drugs FDA Approval 52

The Pharma Data

NOVEMBER 10, 2020

11, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. , (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in November.

Small Molecule 40

Small Molecule Clinical Trials Production Treatment 40

The Pharma Data

JANUARY 19, 2021

The year is starting off with a number of biopharma and life sciences initial public offerings (IPOs). Its lead candidate is CLN-081, an oral small molecule designed to be a next-generation, irreversible EGFR inhibitor. The National Institutes of Health (NIH) is planning on taking over manufacturing and clinical development.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

The Pharma Data

OCTOBER 26, 2020

The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. AR-301 is a fully human IgG1 mAb currently in Phase 3 clinical development targeting gram-positive Staphylococcus aureus ( S.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

Advarra

FEBRUARY 24, 2023

In short, FDA is acknowledging this is complex area, so make sure all clinical development and biostatistical experts are well-versed on how to design these types of trials to ensure startup and/or regulatory approval is not delayed. Bottom line: Designing a clinical trial approach and program is complex.

Clinical Trials 52

Clinical Trials Trials FDA Therapies 52

The Pharma Data

DECEMBER 15, 2020

On top of this, another 8 million carry auto-antibodies, blood molecules that indicate a person’s chance of developing an autoimmune disease. Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. Small Molecule Inhibitors. Oral, Small Molecules.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

JANUARY 10, 2021

“We expect 2021 will mark a number of key clinical and commercial milestones. By the end of the year, we expect to have five independent TransCon product candidates in clinical development leveraging TransCon technologies through our algorithm for product innovation. Pipeline Updates. •. .

Clinical Trials 40

Clinical Trials Clinical Development Small Molecule Trials 40

Agency IQ

JULY 26, 2024

Postapproval manufacturing changes for biological products During clinical development or following a product’s approval , sponsors and/or manufacturers may identify the need for a change in the product, production process, quality controls, equipment, facilities, responsible personnel, or labeling. Any CMC changes (e.g.,

Biosimilars 40

Biosimilars Science FDA Production 40

The Pharma Data

NOVEMBER 5, 2020

Taveras will lead all research and non-clinical development functions supporting the company’s pipeline of investigational therapies. Prior to that, Taveras was vice president of Small Molecule Drug Discovery and CMC Development at Biogen Idec, and Alantos Pharmaceuticals, which was acquired by Amgen in 2007.

Analytical Chemistry 40

Analytical Chemistry Pharmaceuticals Small Molecule Therapies 40

The Pharma Data

JANUARY 3, 2021

Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. SOUTH SAN FRANCISCO, Calif.,

Trials 52

Trials Clinical Trials Small Molecule Therapies 52

The Pharma Data

OCTOBER 14, 2020

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Ilya Trakht, Ph.D., The study led by Dr. Sergei Rudchenko, Ph.D., 1 Noyce RS, et al. 2018) PLoS One. 13(1):e0188453.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

APRIL 11, 2023

Both small molecule inhibitors in Immuno-Oncology are being jointly developed in a strategic research alliance with the German Cancer Research Center (DKFZ) in Heidelberg, Germany. The company has the passion and determination to develop innovative medicines that help improve and extend the lives of people living with cancer.

Research 40

Research Clinical Trials Small Molecule Trials 40

The Pharma Data

AUGUST 29, 2020

3,4 LNP023 is currently in clinical development for PNH and a number of renal conditions with complement system involvement where significant unmet needs exist, including IgA nephropathy, complement 3 glomerulopathy (C3G), atypical hemolytic uremic syndrome and membranous nephropathy. Blood 2019;134(Suppl 1):3517.

Treatment 52

Treatment Disease Small Molecule Production 52

The Pharma Data

SEPTEMBER 2, 2020

“While conditions of the nervous system are some of the most complex to understand and treat, we are committed to following the science to reduce relapses in NMOSD and slow and eventually stop disease progression in MS,” said Levi Garraway, M.D., Roche’s Chief Medical Officer and Head of Global Product Development.

Clinical Trials 52

Clinical Trials Disease Treatment Therapies 52

The Pharma Data

DECEMBER 12, 2020

Both companies share the same dedication to science and innovation to deliver life-changing medicines. AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. Strategic rationale.

Regulations 75

Regulations International Disease Small Molecule 75

The Pharma Data

SEPTEMBER 9, 2020

Both collaborators are committed to developing these novel vaccines with preclinical and clinical data at the forefront of all their decision making. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

SEPTEMBER 9, 2020

Assuming clinical success, Pfizer and BioNTech are on track to seek regulatory review for BNT162b2 as early as October 2020 and, if regulatory authorization or approval is obtained, currently plan to supply up to 100 million doses worldwide by the end of 2020 and approximately 1.3 billion doses by the end of 2021.

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

The Pharma Data

NOVEMBER 9, 2020

Today is a great day for science and humanity. This is a victory for innovation, science and a global collaborative effort,” said Prof. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Ugur Sahin, BioNTech co-founder and CEO.

Vaccine 40

Vaccine Clinical Trials Trials FDA 40

The Pharma Data

DECEMBER 11, 2020

Historic science-driven efforts will seek to help bring an end to the most devastating pandemic in a century. company, today’s news brings great pride and tremendous joy that Pfizer has risen to the challenge to develop a vaccine that has the potential to help bring an end to this devastating pandemic.

Vaccine 52

Vaccine Clinical Trials Trials Licensing 52

The Pharma Data

MAY 7, 2021

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

NOVEMBER 20, 2020

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

Vaccine 52

Vaccine FDA Clinical Trials Trials 52

The Pharma Data

AUGUST 20, 2020

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

The Pharma Data

JULY 21, 2021

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

MAY 6, 2021

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52